Cwm LLC Has $11.77 Million Holdings in Moderna, Inc. (NASDAQ:MRNA)

Cwm LLC lifted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 27.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 118,335 shares of the company’s stock after purchasing an additional 25,209 shares during the period. Cwm LLC’s holdings in Moderna were worth $11,768,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the business. Cim Investment Management Inc. raised its stake in Moderna by 4.2% during the first quarter. Cim Investment Management Inc. now owns 2,139 shares of the company’s stock worth $329,000 after buying an additional 86 shares during the last quarter. Cetera Advisor Networks LLC raised its stake in Moderna by 0.5% during the fourth quarter. Cetera Advisor Networks LLC now owns 17,195 shares of the company’s stock worth $3,088,000 after buying an additional 87 shares during the last quarter. Ancora Advisors LLC raised its stake in Moderna by 41.2% during the first quarter. Ancora Advisors LLC now owns 329 shares of the company’s stock worth $51,000 after buying an additional 96 shares during the last quarter. Sunbelt Securities Inc. raised its stake in Moderna by 7.5% during the first quarter. Sunbelt Securities Inc. now owns 1,428 shares of the company’s stock worth $211,000 after buying an additional 100 shares during the last quarter. Finally, Allworth Financial LP raised its stake in Moderna by 6.5% during the fourth quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after buying an additional 101 shares during the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Insider Buying and Selling

In related news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction dated Wednesday, April 17th. The shares were sold at an average price of $103.38, for a total transaction of $1,550,700.00. Following the transaction, the director now directly owns 2,056,931 shares in the company, valued at $212,645,526.78. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CFO James M. Mock sold 647 shares of the business’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $94.57, for a total transaction of $61,186.79. Following the transaction, the chief financial officer now directly owns 4,300 shares in the company, valued at $406,651. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction dated Wednesday, April 17th. The stock was sold at an average price of $103.38, for a total transaction of $1,550,700.00. Following the transaction, the director now owns 2,056,931 shares in the company, valued at $212,645,526.78. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 109,954 shares of company stock worth $11,533,976. 15.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

MRNA has been the subject of a number of analyst reports. Jefferies Financial Group reissued a “buy” rating and set a $125.00 target price on shares of Moderna in a research note on Tuesday, April 9th. William Blair reissued a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Oppenheimer raised shares of Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 target price for the company in a research note on Tuesday, January 2nd. Canaccord Genuity Group lifted their price target on shares of Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a research note on Friday, February 23rd. Finally, HSBC reaffirmed a “reduce” rating and issued a $86.00 price target (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $126.49.

Moderna Trading Down 0.6 %

NASDAQ:MRNA opened at $101.41 on Monday. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.42 and a quick ratio of 3.36. The firm has a 50-day moving average of $100.63 and a 200-day moving average of $93.50. The company has a market cap of $38.83 billion, a PE ratio of -8.17 and a beta of 1.62. Moderna, Inc. has a one year low of $62.55 and a one year high of $144.43.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, topping the consensus estimate of ($0.78) by $1.33. The company had revenue of $2.80 billion during the quarter, compared to the consensus estimate of $2.53 billion. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The firm’s revenue for the quarter was down 44.9% on a year-over-year basis. During the same period in the previous year, the firm posted $3.61 earnings per share. As a group, equities research analysts expect that Moderna, Inc. will post -7.51 EPS for the current fiscal year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.